Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaxanib + Irinotecan in Advanced Colorectal Cancer
NCT00005818Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2000
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaxanib in colorectal carcinoma (CRC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicity and 1 more. Started Mar 2000; status: completed.
02
Drugs
semaxanib
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00005818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005818.